Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

Myopic Choroidal Neovascularisation Clinical Trial

Official title:
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

Status Completed

Clinical Trial Summary

Choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV) is a common vision-threatening complication and often affects adults of working age. Intravitreal injection of any anti-vascular endothelial growth factor (VEGF) drugs would significantly suppress the activity of the CNV and finally improve the visual acuity. However, more than half of the patients would need one or more further injection for the recurrence or uncontrolled with 1+pro re nata (PRN) treatment within one year, and whether increasing the initial loading of intravitreal injection of anti-VEGF would be more efficacy for the controlling the PM-CNV remained unknown.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03971162
Study type	Interventional
Source	Zhongshan Ophthalmic Center, Sun Yat-sen University
Contact
Status	Completed
Phase	N/A
Start date	June 13, 2019
Completion date	January 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05677685` - VISUPRIME® Eye Drops	N/A
Active, not recruiting	`NCT03797547` - Real Life Study in Myopic Neovascularization
Recruiting	`NCT05494775` - Effect of Corona Virus on Intravitreal Injections	N/A
Suspended	`NCT04222842` - CM082 in Patients With Myopic Choroidal Neovascularization (CNV)	Phase 1
Not yet recruiting	`NCT06357559` - OCTA Changes in Choroidal Neovascularization in High Myopia